Latest News and Press Releases

SAN DIEGO, March 20, 2026 (GLOBE NEWSWIRE) -- Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of...

马萨诸塞州沃尔瑟姆, March 20, 2026 (GLOBE NEWSWIRE) --...

Kensington, MD, USA and Munich/Martinsried, Germany, March 20, 2026 (GLOBE NEWSWIRE) -- Prodrug of oral amyloid beta aggregation modulator demonstrated improved absorption characteristics, leading...

SUNNYVALE, Calif., March 19, 2026 (GLOBE NEWSWIRE) -- BioCardia®, Inc. [NASDAQ:BCDA], a developer of cellular and cell-derived therapeutics for the treatment of cardiovascular and pulmonary...

-- Topline data from Phase 3 OnPrime/GOG-3076 ovarian cancer registrational trial of Olvi-Vec expected in 2H26 -- -- Interim systemic lung cancer data with Olvi-Vec demonstrated partial responses in...

Record full year 2025 net sales of $32.0, an increase of 27% over $25.2 million for the full year 2024 driven by 25% annual growth in our U.S. prescription business and 97% increase in general...

– Positive Phase 3 topline results demonstrating envudeucitinib’s leading skin clearance, meaningful symptom improvement and a favorable safety profile in patients with moderate-to-severe plaque...

SANGAMO THERAPEUTICS ANNOUNCES FOURTH QUARTER AND FULL YEAR 2025 EARNINGS CALL

Positive 12-month Phase 2 data for NDV-01 in non-muscle invasive bladder cancer (NMIBC) demonstrated a 95% complete response (CR) rate at any time and a durable 76% CR rate at 12 months, with...

Company AnnouncementCOPENHAGEN, Denmark; March 19, 2026 – Genmab A/S (Nasdaq: GMAB) Following Genmab A/S’ Annual General Meeting held on March 19, 2026, the Company’s Board of Directors met to...